Assessing the efficacy and safety for novel drug candidates for Alzheimer's disease employs a rigorous evaluation framework. Preclinical studies usually involve in vitro and in vivo models to assess a potential efficacy in targeting disease-related pathways. Once promising candidates emerge, they undergo clinical trials that are conducted on human